462 related articles for article (PubMed ID: 19906266)
1. Biomarkers in Alzheimer's disease: not yet surrogate endpoints.
Coley N; Andrieu S; Delrieu J; Voisin T; Vellas B
Ann N Y Acad Sci; 2009 Oct; 1180():119-24. PubMed ID: 19906266
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers in preclinical Alzheimer's disease.
Chong MS; Lim WS; Sahadevan S
Curr Opin Investig Drugs; 2006 Jul; 7(7):600-7. PubMed ID: 16869111
[TBL] [Abstract][Full Text] [Related]
3. Relevance of the evaluation criteria used in clinical trials for Alzheimer's disease.
Truffinet P; Bordet R; Ménard J
Therapie; 2009; 64(3):139-8. PubMed ID: 19671425
[TBL] [Abstract][Full Text] [Related]
4. Defining and labeling disease-modifying treatments for Alzheimer's disease.
Cummings JL
Alzheimers Dement; 2009 Sep; 5(5):406-18. PubMed ID: 19751920
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers in clinical trials for neurodegenerative diseases: regulatory perspectives and requirements.
Broich K; Weiergräber M; Hampel H
Prog Neurobiol; 2011 Dec; 95(4):498-500. PubMed ID: 21945642
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers in Alzheimer's disease drug development.
Cummings JL
Alzheimers Dement; 2011 May; 7(3):e13-44. PubMed ID: 21550318
[TBL] [Abstract][Full Text] [Related]
7. AddNeuroMed--the European collaboration for the discovery of novel biomarkers for Alzheimer's disease.
Lovestone S; Francis P; Kloszewska I; Mecocci P; Simmons A; Soininen H; Spenger C; Tsolaki M; Vellas B; Wahlund LO; Ward M;
Ann N Y Acad Sci; 2009 Oct; 1180():36-46. PubMed ID: 19906259
[TBL] [Abstract][Full Text] [Related]
8. [The Alzheimer's disease: how to estimate the impact of the pathology and the treatment?].
Delrieu J; Vellas B
Therapie; 2010; 65(5):423-8. PubMed ID: 21144477
[TBL] [Abstract][Full Text] [Related]
9. Structural neuroimaging outcomes in clinical dementia trials, with special reference to disease modifying designs.
Scheltens P; Barkhof F
J Nutr Health Aging; 2006; 10(2):123-8; discussion 129-30. PubMed ID: 16554946
[TBL] [Abstract][Full Text] [Related]
10. Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020.
Hampel H; Lista S; Teipel SJ; Garaci F; Nisticò R; Blennow K; Zetterberg H; Bertram L; Duyckaerts C; Bakardjian H; Drzezga A; Colliot O; Epelbaum S; Broich K; Lehéricy S; Brice A; Khachaturian ZS; Aisen PS; Dubois B
Biochem Pharmacol; 2014 Apr; 88(4):426-49. PubMed ID: 24275164
[TBL] [Abstract][Full Text] [Related]
11. Disease-modifying therapies for Alzheimer disease: challenges to early intervention.
Cummings JL; Doody R; Clark C
Neurology; 2007 Oct; 69(16):1622-34. PubMed ID: 17938373
[TBL] [Abstract][Full Text] [Related]
12. Magnetic resonance markers for early diagnosis and progression of Alzheimer's disease.
Kantarci K
Expert Rev Neurother; 2005 Sep; 5(5):663-70. PubMed ID: 16162090
[TBL] [Abstract][Full Text] [Related]
13. [Surrogate and true endpoints in cancer clinical trials].
Nakajima T; Ohta K; Ohyama S; Yamaguchi T
Gan To Kagaku Ryoho; 2000 May; 27(5):671-5. PubMed ID: 10832433
[TBL] [Abstract][Full Text] [Related]
14. Change in MRI striatal volumes as a biomarker in preclinical Huntington's disease.
Aylward EH
Brain Res Bull; 2007 Apr; 72(2-3):152-8. PubMed ID: 17352939
[TBL] [Abstract][Full Text] [Related]
15. Use of meta-analysis for the validation of surrogate endpoints and biomarkers in cancer trials.
Buyse M
Cancer J; 2009; 15(5):421-5. PubMed ID: 19826362
[TBL] [Abstract][Full Text] [Related]
16. Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema.
Lassere MN; Johnson KR; Boers M; Tugwell P; Brooks P; Simon L; Strand V; Conaghan PG; Ostergaard M; Maksymowych WP; Landewe R; Bresnihan B; Tak PP; Wakefield R; Mease P; Bingham CO; Hughes M; Altman D; Buyse M; Galbraith S; Wells G
J Rheumatol; 2007 Mar; 34(3):607-15. PubMed ID: 17343307
[TBL] [Abstract][Full Text] [Related]
17. [Biomarkers of Alzheimer's disease].
Shoji M
Rinsho Shinkeigaku; 2004 Nov; 44(11):771-4. PubMed ID: 15651287
[TBL] [Abstract][Full Text] [Related]
18. Biomarkers for Alzheimer's disease.
Ward M
Expert Rev Mol Diagn; 2007 Sep; 7(5):635-46. PubMed ID: 17892369
[TBL] [Abstract][Full Text] [Related]
19. Surrogate endpoints and newer risk markers in atherosclerosis management.
Ballantyne CM
Am J Manag Care; 2001 May; 7(5 Suppl):S144-7. PubMed ID: 11383376
[TBL] [Abstract][Full Text] [Related]
20. Optimizing the use of biomarkers, surrogate endpoints, and clinical endpoints for more efficient drug development.
Colburn WA
J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1419-27. PubMed ID: 11185662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
